Mark A. Ator

4.4k total citations
91 papers, 3.1k citations indexed

About

Mark A. Ator is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Mark A. Ator has authored 91 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 33 papers in Oncology and 16 papers in Immunology. Recurrent topics in Mark A. Ator's work include Peptidase Inhibition and Analysis (10 papers), Calpain Protease Function and Regulation (9 papers) and Cancer therapeutics and mechanisms (9 papers). Mark A. Ator is often cited by papers focused on Peptidase Inhibition and Analysis (10 papers), Calpain Protease Function and Regulation (9 papers) and Cancer therapeutics and mechanisms (9 papers). Mark A. Ator collaborates with scholars based in United States, France and Germany. Mark A. Ator's co-authors include P.R. Ortiz de Montellano, Roland E. Dolle, Thelma S. Angeles, Carla T. Helaszek, JoAnne Stubbe, J. Stubbe, Bruce Ruggeri, Robert L. Hudkins, John P. Mallamo and Stanley J. Schmidt and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Mark A. Ator

91 papers receiving 2.9k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark A. Ator 1.8k 772 602 462 379 91 3.1k
Jianguo Ji 2.0k 1.1× 290 0.4× 1.5k 2.5× 306 0.7× 232 0.6× 129 4.4k
Jeffrey A. Dodge 1.4k 0.8× 364 0.5× 1.1k 1.8× 205 0.4× 200 0.5× 68 3.4k
Jonathan M. Elkins 2.8k 1.6× 672 0.9× 497 0.8× 319 0.7× 161 0.4× 73 4.0k
Bhaskar C. Das 1.4k 0.8× 322 0.4× 798 1.3× 122 0.3× 237 0.6× 111 3.4k
Žaklina Kovačević 3.2k 1.8× 1.8k 2.3× 749 1.2× 297 0.6× 204 0.5× 89 5.6k
Cynthia Hong 2.2k 1.2× 682 0.9× 807 1.3× 337 0.7× 1.4k 3.7× 56 5.6k
Patric J. Jansson 2.6k 1.4× 2.4k 3.1× 981 1.6× 417 0.9× 183 0.5× 85 5.5k
Rodolfo Márquez 1.7k 1.0× 332 0.4× 1.2k 2.0× 136 0.3× 215 0.6× 94 3.3k
Sumit Sahni 1.9k 1.0× 1.1k 1.4× 310 0.5× 125 0.3× 196 0.5× 90 3.6k
Glenn C. Andrews 1.2k 0.7× 832 1.1× 954 1.6× 152 0.3× 148 0.4× 39 2.7k

Countries citing papers authored by Mark A. Ator

Since Specialization
Citations

This map shows the geographic impact of Mark A. Ator's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Ator with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Ator more than expected).

Fields of papers citing papers by Mark A. Ator

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Ator. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Ator. The network helps show where Mark A. Ator may publish in the future.

Co-authorship network of co-authors of Mark A. Ator

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Ator. A scholar is included among the top collaborators of Mark A. Ator based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Ator. Mark A. Ator is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mason, Jennifer L., et al.. (2015). A Cellular Assay for Inhibitors of the Fatty Acid Biosynthetic Pathway Using Scintillating Microplates. Assay and Drug Development Technologies. 13(5). 285–292. 1 indexed citations
3.
Mason, Jennifer L., Jean Husten, Mark S. Albom, et al.. (2012). Comparison of LanthaScreen Eu Kinase Binding Assay and Surface Plasmon Resonance Method in Elucidating the Binding Kinetics of Focal Adhesion Kinase Inhibitors. Assay and Drug Development Technologies. 10(5). 468–475. 7 indexed citations
4.
Mason, Jennifer L., Mark S. Albom, S. N. Prasanna Murthy, et al.. (2012). Time-Resolved Fluorescence Resonance Energy Transfer as a Versatile Tool in the Development of Homogeneous Cellular Kinase Assays. Assay and Drug Development Technologies. 10(6). 551–557. 1 indexed citations
5.
Dunn, Derek W., et al.. (2012). Wake-promoting agents: Search for next generation modafinil: Part II. Bioorganic & Medicinal Chemistry Letters. 22(6). 2315–2317. 2 indexed citations
6.
Cheng, Mangeng, Matthew R. Quail, Diane E. Gingrich, et al.. (2011). CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. Molecular Cancer Therapeutics. 11(3). 670–679. 59 indexed citations
7.
Raddatz, Rita, Robert L. Hudkins, Joanne R. Mathiasen, et al.. (2011). CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting Activities. Journal of Pharmacology and Experimental Therapeutics. 340(1). 124–133. 52 indexed citations
8.
Dunn, Derek, Mohamed Iqbal, John A. Gruner, et al.. (2011). Wake-promoting agents: Search for next generation modafinil: Part I. Bioorganic & Medicinal Chemistry Letters. 22(6). 2312–2314. 7 indexed citations
9.
Mason, Jennifer L., Beverly P. Holskin, Kristen A. Murray, et al.. (2010). Modification of CellSensor irf1- bla TF-1 and irf1- bla HEL Assays for Direct Comparison of Wild-Type JAK2 and JAK2 V617F Inhibition. Assay and Drug Development Technologies. 9(3). 311–318. 3 indexed citations
10.
Ruggeri, Bruce, Ted L. Underiner, Diane E. Gingrich, et al.. (2007). CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models. Molecular Cancer Therapeutics. 6. 2 indexed citations
11.
Miknyoczki, Sheila, Jennifer V. Grobelny, Allison L. Zulli, et al.. (2005). The selective PARP inhibitor, CEP-8983 exhibits significant chemosensitization in combination with TMZ and SN38 against chemoresistant tumor cell lines and xenografts. Cancer Research. 65. 1206–1207. 1 indexed citations
12.
Wells, Gregory J., Ron Bihovsky, Robert L. Hudkins, Mark A. Ator, & Jean Husten. (2005). Synthesis and structure–activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorganic & Medicinal Chemistry Letters. 16(5). 1151–1155. 15 indexed citations
13.
Tao, Ming, Ron Bihovsky, Gregory J. Wells, et al.. (2005). Synthesis and structure–activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(4). 938–942. 41 indexed citations
14.
Murakata, Chikara, Masami Kaneko, George Gessner, et al.. (2002). Mixed lineage kinase activity of indolocarbazole analogues. Bioorganic & Medicinal Chemistry Letters. 12(2). 147–150. 83 indexed citations
15.
Tripathy, Rabindranath, et al.. (1998). P2-proline-derived inhibitors of calpain I. Bioorganic & Medicinal Chemistry Letters. 8(19). 2647–2652. 10 indexed citations
16.
Malinowski, John, Bruce Grasberger, G M Trakshel, et al.. (1995). Production, purification, and crystallization of human interleukin‐1β converting enzyme derived from an Escherichia coli expression system. Protein Science. 4(10). 2149–2155. 4 indexed citations
17.
Salowe, Scott P., J. Martin Bollinger, Mark A. Ator, et al.. (1993). Alternative model for mechanism-based inhibition of Escherichia coli ribonucleotide reductase by 2'-azido-2'-deoxyuridine 5'-diphosphate. Biochemistry. 32(47). 12749–12760. 49 indexed citations
18.
Ator, Mark A., et al.. (1992). Synthesis, specificity, and antifungal activity of inhibitors of the Candida albicans .DELTA.24-sterol methyltransferase. Journal of Medicinal Chemistry. 35(1). 100–106. 39 indexed citations
19.
Ohlstein, Eliot H., et al.. (1990). Biosynthesis and modulation of endothelin from bovine pulmonary arterial endothelial cells. Life Sciences. 46(3). 181–188. 30 indexed citations
20.
Montellano, Paul R. Ortiz de, et al.. (1988). Mechanism-based inactivation of horseradish peroxidase by sodium azide. Formation of meso-azidoprotoporphyrin IX. Biochemistry. 27(15). 5470–5476. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianguo Ji Breakdown of academic impact, for papers by Jeffrey A. Dodge Breakdown of academic impact, for papers by Jonathan M. Elkins Breakdown of academic impact, for papers by Bhaskar C. Das Breakdown of academic impact, for papers by Žaklina Kovačević Breakdown of academic impact, for papers by Cynthia Hong Breakdown of academic impact, for papers by Patric J. Jansson Breakdown of academic impact, for papers by Rodolfo Márquez Breakdown of academic impact, for papers by Sumit Sahni Breakdown of academic impact, for papers by Glenn C. Andrews
Rankless by CCL
2026